Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

International journal of hematology - 1 Oct 2021

Yasuda Shunichiro, Aoyama Satoru, Yoshimoto Ryoto, Li Huixin, Watanabe Daisuke, Akiyama Hiroki, Yamamoto Kouhei, Fujiwara Takeo, Najima Yuho, Doki Noriko, Sakaida Emiko, Edahiro Yoko, Imai Misa, Araki Marito, Komatsu Norio, Miura Osamu, Kawamata Norihiko

Abstract excerpt

Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations. However, many MPN patients develop resistance to RUX. Although mechanisms of RUX-resistance in cells with JAK2V617 F have already been characterized, those in cells with CALR mutations remain to be elucidated. In this study, we established RUX-resistant human cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Disease Management

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Megakaryocytes

Share to Myeloproliferative Disorders

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Receptors, Thrombopoietin

Source

Identifiers

PMID: 34165774
DOI: 10.1007/s12185-021-03180-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.PMID 34165774Read ↗

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.Semantic proximity Read ↗

Targeting the CALR interactome in myeloproliferative neoplasmsSemantic proximity Read ↗

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasmsSemantic proximity Read ↗

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.Semantic proximity Read ↗

Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.Semantic proximity Read ↗

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.Semantic proximity Read ↗

Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.Semantic proximity Read ↗

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Semantic proximity Read ↗

Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulinSemantic proximity Read ↗

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read ↗

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.